Comparative Pharmacology
Head-to-head clinical analysis: CIALIS versus TADALAFIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CIALIS versus TADALAFIL.
CIALIS vs TADALAFIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Phosphodiesterase-5 (PDE5) inhibitor; increases cGMP levels, causing smooth muscle relaxation and vasodilation in the corpus cavernosum, enhancing erectile function.
Inhibitor of phosphodiesterase type 5 (PDE5), enhancing cyclic guanosine monophosphate (cGMP)-mediated relaxation of smooth muscle in the corpus cavernosum and pulmonary vasculature.
Tadalafil 10 mg or 20 mg orally as needed at least 30 minutes before sexual activity; maximum dosing frequency once daily. Alternative: 2.5 mg or 5 mg once daily for daily use.
Erectile dysfunction: 10-20 mg orally as needed, 30-60 minutes before sexual activity; maximum 1 dose per day. Benign prostatic hyperplasia: 5 mg orally once daily. Pulmonary arterial hypertension: 40 mg orally once daily.
None Documented
None Documented
Clinical Note
moderateTadalafil + Torasemide
"Tadalafil may increase the antihypertensive activities of Torasemide."
Clinical Note
moderateTadalafil + Travoprost
"Tadalafil may increase the antihypertensive activities of Travoprost."
Clinical Note
moderateTadalafil + Unoprostone
"Tadalafil may increase the antihypertensive activities of Unoprostone."
Clinical Note
moderateTadalafil + Hydrochlorothiazide
"Tadalafil may increase the antihypertensive activities of Hydrochlorothiazide."
The terminal elimination half-life of tadalafil is approximately 17.5 hours in healthy subjects, which supports once-daily dosing for erectile dysfunction and once-daily use for benign prostatic hyperplasia. This long half-life distinguishes it from other PDE5 inhibitors.
Terminal elimination half-life is 17.5 hours in healthy subjects; supports once-daily dosing and prolonged effect (up to 36 hours for erectile function).
Following oral administration, tadalafil is predominantly eliminated by hepatic metabolism. The metabolites are excreted mainly in feces (approximately 61% of the dose) and to a lesser extent in urine (approximately 36% of the dose). No unchanged parent drug is detected in urine.
Primarily hepatic metabolism (CYP3A4); 36% excreted in urine (mainly metabolites), 61% in feces (mainly metabolites), <0.1% unchanged in urine.
Category C
Category A/B
PDE5 Inhibitor
PDE5 Inhibitor